Early lab and animal studies suggest that Spyryx Biosciences’ drug candidate SPX-101 will be a safe and effective way of  improving mucus clearance in patients with cystic fibrosis (CF), regardless of the underlying mutation(s) causing their disease. The data were presented at the 30th Annual North American Cystic Fibrosis…

Alcresta Therapeutics announced that its product RELiZORB effectively increased fat absorption in cystic fibrosis (CF) patients receiving enteral tube feeding and who have trouble breaking down and absorbing these molecules, resulting in reduced frequency and severity of gastrointestinal symptoms among those patients. The findings were presented at the 30th…

A transition from youth to adult cystic fibrosis (CF) care needs to be guided by formal programs to maximize patient satisfaction and health outcomes. For successful transitions, skills essential to managing independent adult care also need to be developed, and assessing such skills before attempting a transfer would be wise. The “…

In a recent talk titled “Implementation of Colorectal Guidelines,” Alexander Khoruts, MD, from the University of Minnesota, discussed recommendations for an effective screening for colorectal cancer in patients with cystic fibrosis (CF). The talk was presented at the 30th Annual North American Cystic Fibrosis Conference Oct. 27-29 in Orlando, Florida. Patients…

Substantial health benefits can be gained by cystic fibrosis (CF) patients who exercise more, but to accurately assess the impact of such interventions, physicians need to test for exercise capacity and habitual physical activity. In the session, “Let’s Get Moving: Best Practices in Exercise & Physical Activity…

The importance of investigating the role of the airway microbiome in lung damage associated with cystic fibrosis (CF) was the focus of two talks at the recent 30th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Florida. Both talks were based on the topic, “Microbiome Studies Can be Helpful in Understanding CF Infections.” CF and CF manifestations, particularly…

Developing a vaccine against infections in patients with cystic fibrosis (CF) is challenging, and to succeed researchers need a deeper understanding of the natural history of CF lung infections. Joanna Goldberg, PhD, with Emory University School of Medicine, detailed the difficulties specific to such vaccine discovery in her talk, “Vaccines for CF Infections: Episode…

TGV-inhalonix reported  that its therapeutic agent Mul-1867  is continuing to show promise in treating antibiotic-resistant lung infections — namely, mixed bacterial and fungal infections — in patients with cystic fibrosis (CF), and it is planning to bring the treatment into clinical testing in the U.S. within two years. Data…

In a recent talk, researchers showed the enhanced benefits of two next-generation CFTR correctors in cystic fibrosis (CF) patients with specific mutations. The positive results support the clinical evaluation of both drugs in early-stage clinical trials. The talk, “Discovery and biological profile of next-generation CFTR correctors,” was recently presented at the…

Fewer than half of the cystic fibrosis (CF) patients eligible for treatment with Orkambi (lumacaftor/ivacaftor) used the medication at the end of its first year on the market, an especially low number when compared to the spread of Kalydeco (ivacaftor) use. The study, “Uptake of Lumacaftor-Ivacaftor Use…